License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended September 30,				Nine months ended September 30,
Partner	Drug or Drug Candidate	2019		2018		2019		2018
Bristol-Myers Squibb Company	NKTR-214	$	—	$	—	$	—	$	1,059,768
Eli Lilly and Company	NKTR-358	1,500		3,221		5,200		8,627
Amgen, Inc.	Neulasta®	1,250		1,250		3,750		3,750
Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other	ADYNOVATE®	371		404		910		10,703
License, collaboration and other revenue		$	3,121	$	4,875	9,860		$	1,082,848

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the nine months ended September 30, 2019 (in thousands):

	Nine months ended September 30, 2019
Deferred revenue—December 31, 2018	$	24,636
Recognition of previously unearned revenue	(9,465		)
Deferred revenue—September 30, 2019	$	15,171